In the News
Demand for pathology services sparks PPD, NeoGenomics alliance
Collaboration to provide a seamless and fully integrated global pathology and molecular testing solution to PPD’s pharmaceutical and biotech clients.
PPD proposes finding patients first, activating sites second
Roger Smith explains how PatientAdvantage enables PPD to rapidly enroll community-based patients from its proprietary databases and modeling.
PPD, NeoGenomics to integrate pathology testing for cancer trials
Collaboration will enable both companies to jointly provide a premier global oncology and specialty laboratory solution for customers.
China Regulatory Reform: An Update on Review Timelines and Drug Lag
Alistair Davidson, Kirsten Messmer and Bill Wang describe the importance of China’s most recent regulatory reform and its impact on the pharmaceutical industry.
CRO’s FSP model proves to be the right choice
Gary Barker, Denise Moody, April Pierce and Magda Santos explain how PPD used an FSP model to help build a solid, long-term partnership with a top 25 pharmaceutical organization.
CRO Industry Update: Big Data Drives Drug Development Efforts
PPD’s David Johnston and Evidera’s Eric Faulkner comment on the changing clinical development landscape.
Today’s Feasibility Challenge: Harnessing Data to Deliver Patients into Clinical Trials
Gaurav Bhatnagar discusses how data-driven feasibility assessment is at the heart of the emerging evidence-based clinical trial process.
FDA Regenerative Medicine Policy Framework and Advanced Therapy Designation
Richard Dennett and Kirsten Messmer provide an overview of the policy framework established by the U.S. Food and Drug Administration for the regulation of regenerative medicine and advanced therapies.
PPD becomes first CRO partner for MIT’s initiative
Initiative provides its members an environment, programs and practices for open, non-competitive collaboration.
